Matthew Davenport

Matthew Davenport has extensive experience in various roles within the medical and engineering fields. Matthew is currently serving as the Director of Operations at LifeSprout since June 2020.

Prior to this, Matthew worked at Gemstone Biotherapeutics as the Director of Engineering from June 2014 to June 2020. In this role, they directed research and development efforts for a medical device focused on skin regeneration. Matthew also collaborated with the FDA, contract manufacturers, and key CROs. Matthew has valuable experience in developing and executing in vitro and in vivo assays throughout product development.

Before joining Gemstone Biotherapeutics, Matthew worked as a Graduate Researcher in the Gerecht Lab at Johns Hopkins University from September 2011 to June 2014. Additionally, they served as an Advanced Process Engineering Intern at Myriant Corporation from May 2013 to August 2013, and as a Cellulosic Intern at Myriant Technologies, LLC from May 2010 to January 2013.

Furthermore, Matthew gained research experience as a Trainee at the European Molecular Biology Laboratory in 2011. Their work focused on studying small RNAs called piwi-interacting RNAs (piRNA) found in mammalian testes. Matthew investigated the interaction between non-coding piRNAs and Argonaut proteins, particularly the Miwi domain, and its implications on transposon silencing and infertility. Matthew utilized various biochemical protocols and techniques for purification, labeling, analysis, and tagging during their research.

Matthew Davenport has pursued their education in the field of Chemical and Biomolecular Engineering. Matthew obtained a Bachelor of Science degree from The Johns Hopkins University, which they attended from 2009 to 2013. Subsequently, they continued their studies at The Johns Hopkins University, where they earned a Master of Science (M.Sc.) degree in Chemical and Biomolecular Engineering from 2013 to 2014.